AHFS Drug Information

AHFS-DI-200x242

The 2016 edition of AHFS DI, which marks 58 years of continuous publication, contains extensively updated monographs and revised therapeutic guidelines, including revised recommendations for the treatment of HIV infections in adult and pediatric patients. It also presents new information on breakthrough oncology drugs approved as part of the Food and Drug Administration (FDA) Accelerated Approval Program.

Each year, AHFS DI expands it database by dozens of new drug monographs and incorporates emerging information on cautions, drug interactions, and therapeutic perspectives. The new 2016 edition includes revised information about:

  • Orphan drug products.
  • Therapeutic recommendations supported by evidence from primary research.
  • Extensive dosage and administration information.
  • Pharmacology and pharmacokinetics.
  • Prescription, OTC, ophthalmic and dermatologic drugs.
  • Extensive off-label uses and related dosing options.
  • Vaccines and other immunizing agents.

AHFS DI is the only printed compendium designated by the U.S. Congress as a source for reimbursement of off-label uses. The Centers for Medicare & Medicaid Services and numerous healthcare insurance providers recognize it as a definitive reference on the medically accepted uses of drugs. Unlike most compendia, recognition of the authority of AHFS DI in establishing medically accepted drug uses extends far beyond cancer drugs to include the full spectrum of drug therapy. Both the National Association of Boards of Pharmacy and the American College of Physicians have listed AHFS DI as a recommended item for inclusion in reference libraries.

Drug monographs in AHFS DI are thoroughly researched by drug information pharmacists and professional editorial and analytical staff. Authors incorporate clinical research findings, guidelines, and FDA-approved labeling into the monographs. The information also reflects the expertise of leading medical scientists, physicians, pharmacists, pharmacologists, and other clinicians, and incorporates the latest therapeutic recommendations from groups like the US Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the American Academy of Pediatrics, the American Heart Association, and many others.

AHFS DI remains the compendium that offers insight into the evidence behind the answers. Approximately 1400 monographs cover information on indications, dosage and administration, contraindications, side effects, drug interactions, pharmacology and pharmacokinetics, chemistry and stability, and more.

Updated monthly and available in XML.

Contact us for a quote and more information.